Pfizer and Flagship form $100M partnership to discover and develop novel drugs

Pfizer and Flagship Pioneering are jointly investing $100 million to fund 10 potential new drug programs.
Flagship's Pioneering Medicines will lead the discovery research, while Pfizer will handle development and have the option to acquire the drugs.
The partnership will utilize Flagship's platform for generating novel technologies and Pfizer's expertise in advancing clinical candidates.
Flagship-backed companies stand to gain up to $700 million in milestones and royalties if any drugs are successfully commercialized.
The collaboration covers disease areas like oncology, immunology, and infectious diseases with limited or no treatment options currently.